Abstracts tagged "Myositis"

Abstract Number: 0299 • ACR Convergence 2023
Trends and Outcomes of Hospitalized Patients with Idiopathic Inflammatory Myopathy and Venous Thromboembolism: A Nationwide Inpatient Sample Analysis from US (2016-2019)
Haseeb Chaudhary¹, Biraj Shrestha², Sarah Abi Doumeth³ and Maya Mattar⁴, ¹Case Western Reserve University, Westlake, OH, ²Tower Health System, Reading, PA, ³Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, ⁴Louis Stokes VA Medical Center, Cleveland, OH
Background/Purpose: Recent evidence suggests increased prevalence of venous thromboembolism (VTE) in patients with idiopathic inflammatory myopathies (IIM). The literature on the clinical implications of VTE…
Abstract Number: 1156 • ACR Convergence 2023
Presentations and Outcomes of Idiopathic Inflammatory Myopathies in Hong Kong
Iris Tang¹, Ho So², Teresa li³, Vivian Tang⁴, Chi Ho⁵ and Roy Ho⁶, ¹Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong, ²Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ³Queen Mary Hospital, Hong Kong, Hong Kong, ⁴North District Hospital, Hong Kong, Hong Kong, ⁵Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong, ⁶Queen Elizabeth Hospital, Hong Kong, Hong Kong
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of heterogeneous autoimmune diseases with cutaneous, musculoskeletal, and systemic involvements. The Hong Kong Myositis Registry (MyoHK) was…
Abstract Number: 1178 • ACR Convergence 2023
Self-Perceived Knowledge of Myositis Among Social Media Respondents- a Pilot Study on Twitter
Srijan Mittal¹, Vanshita Batra¹, Parikshit Sen², Saadia Sasha Ali³, Arpit Mago⁴, Mark Russell⁵, Eugenia Gkiaouraki⁶ and Rohit Aggarwal⁶, ¹Maulana Azad Medical College, New Delhi, India, ²Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, Delhi-110002, India., Dalhi, India, ³King's College Hospital, Epsom, United Kingdom, ⁴Jawaharlal Nehru Medical College, Belgaum, India, ⁵King's College Hospital, London, United Kingdom, ⁶University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Myositis is a rare complex autoimmune disease that is less known and poorly understood, with increased effort required for education of practitioners, students, educators,…
Abstract Number: 1955 • ACR Convergence 2023
Responsiveness and Minimal Important Difference of PROMIS Pain Interference, Fatigue, and Physical Function Forms in Adults with Idiopathic Inflammatory Myopathies
Didem Saygin¹, Dana Direnzo², Joost Raaphorst³, Jin Kyun Park⁴, Ingrid de Groot⁵, Clifton Bingham⁶, Ingrid Lundberg⁷, Malin Regardt⁸, catherine Sarver⁹, Marianne de Visser¹⁰, lara maxwell¹¹, Dorcas Beaton¹², Ju Yeon Kim¹³, Merrilee Needham¹⁴, Helene Alexanderson¹⁵, Lisa Christopher-Stine⁶ and Christopher Mecoli¹⁶, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pennsylvania, Bala Cynwyd, PA, ³Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ⁴Seoul National University Hospital and College of Medicine, Seoul, South Korea, ⁵N/A, Amsterdam, Netherlands, ⁶Johns Hopkins University, Baltimore, MD, ⁷Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden, ⁸Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ⁹N/A, Baltimore, MD, ¹⁰University of Amsterdam, Amsterdam, Netherlands, ¹¹University of Ottawa, Ottawa, ON, Canada, ¹²Institute for Work & Health, Toronto, ON, Canada, ¹³Seoul National University Hospital, Seoul, South Korea, ¹⁴IIID Murdoch University and University of Notre Dame, Perth, Australia, ¹⁵Karolinska Institutet, Stockholm, Sweden, ¹⁶Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Patient reported outcome measures (PROMs) are critical in assessing clinical outcomes. There is a paucity of PROMs for use in patients with adult idiopathic…
Abstract Number: 2464 • ACR Convergence 2023
B Cells in Anti-tRNA Synthetase Syndrome Patients Show an Activated, Interferon Responsive Signature
Erin Wilfong¹, Leslie Crofford² and Rachel Bonami¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Melbourne, AR
Background/Purpose: Autoantibodies directed against various tRNA synthetases defines the anti-tRNA synthetase syndrome (ARS). While it is unclear if the autoantibodies are directly pathogenic, the efficacy…
Abstract Number: 120 • 2023 Pediatric Rheumatology Symposium
The Brazilian Registry of Juvenile Dermatomyositis (JDM): I- Onset Clinical Features and Disease Activity Scores by DAS-20 over 2-Years-Follow Up
Beatriz Carneiro¹, Adriana Elias¹, Teresa Robazzi², Ana Julia Moraes³, Sheila Oliveira⁴, Flavio Sztajnbok⁵, Luciana Carvalho⁶, Luciana Marques⁷, Silvana Sacchetti⁸, Maria Teresa Terreri⁹, Simone Appenzelle¹⁰, Roberto Marini¹¹, Andre Cavalcante¹², Marcia Bandeira¹³, Cristina Magalhaes¹⁴, Melissa Fraga¹⁵, Iloite Scheibel¹⁶, Isabela Daud¹, Darcisio Antonio¹⁷, Claudio Len¹⁸, Clovis Silva¹⁹, Taciana Fernandes¹⁷ and Claudia Magalhaes²⁰, ¹Instituto da Criança - Universidade de São Paulo (USP), São Paulo, Brazil, ²Universidade Federal da Bahia, Brazil, ³Universidade Federal do Para, Brazil, ⁴Universidade Federal do Rio de janeiro, Rio de Janeiro, ⁵Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Brazil, ⁶Universidade de Sao Paulo- Ribeirao Preto, São Paulo, Brazil, ⁷Hospital Albert Sabin, Brazil, ⁸Santa Casa de Sao Paulo, Brazil, ⁹UNIFESP, São Paulo, Brazil, ¹⁰University of Campinas, Campinas, Sao Paulo, Brazil, ¹¹UNICAMP, São Paulo, Brazil, ¹²Hospital Materno-Infantil de Goiania, Brazil, ¹³Hospital Pequeno Principe- Curitiba, Brazil, ¹⁴Hospital Jose de Alencar - Brasilia, Brazil, ¹⁵Hospital Darcy Vargas, Brazil, ¹⁶Hospital Conceição de Porto Alegre, Brazil, ¹⁷Universidade Estadual Paulista (UNESP) Botucatu, Brazil, ¹⁸Universidade Federal de São Paulo - Unifesp, São Paulo, Brazil, ¹⁹Universidade de São Paulo, São Paulo, Brazil, ²⁰São Paulo State University, Pediatric Rheumatology Division, Botucatu, Brazil
Background/Purpose: A national registry was set up, enrolling new onset JDM cases in 18 hospitals, during 3-years (2015-2018) with 2-years follow up, in a low…
Abstract Number: 028 • 2023 Pediatric Rheumatology Symposium
Achieving Medication-Free Remission in Juvenile Dermatomyositis
Harneet Ghumman¹, Ilaria Maccora², Hermine Brunner¹, Amy Cassedy³, Mekibib Altaye², Asra Firdous¹, Alexei Grom¹, Daniel Lovell¹, Angela Merritt¹, Megan Quinlan-Waters¹ and Sheila Angeles-Han², ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by symmetric proximal muscle weakness, distinct rash, and a risk for calcinosis. Systemic immunosuppression is needed. Evidence is limited…
Abstract Number: 064 • 2023 Pediatric Rheumatology Symposium
Towards the Development of Composite Parent-Centered Disease Activity Scores for Juvenile Dermatomyositis
Silvia Rosina¹, Ana Isabel Rebollo-Giménez², Letizia Tarantola³, Roberta Naddei⁴, Alessandro Consolaro², Angela Pistorio⁵ and Angelo Ravelli⁶, ¹IRCCS Istituto Giannina Gaslini, Genova, Italy, ²IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Infiammatorie, Genova, Italy, ³Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genova, Italy, ⁴Università degli Studi di Napoli Federico II, Dipartimento di Scienze Mediche Traslazionali, Napoli, Italy, ⁵IRCCS Istituto Giannina Gaslini, Direzione Scientifica, Genova, Italy, ⁶IRRCS Istituto Giannina Gaslini and Università degli Studi di Genova, Genova, Italy
Background/Purpose: Increasing attention has been recently paid to the development of parent- and child-centered composite DAS for the assessment of health status of children with…
Abstract Number: 100 • 2023 Pediatric Rheumatology Symposium
The Brazilian Registry of Juvenile Dermatomyositis (JDM): II – A Longitudinal Assessment of Muscle Strength by Manual Muscle Test (MMT) and Childhood Myositis Assessment Scale (CMAS) Tools
Darcisio Antonio¹, Taciana Fernandes¹, Adriana Elias², Teresa Robazzi³, Ana Julia Moraes⁴, Sheila Oliveira⁵, Flavio Sztajnbok⁶, Luciana Carvalho⁷, Luciana Marques⁸, Silvana Sacchetti⁹, Maria Teresa Terreri¹⁰, Simone Appenzelle¹¹, Roberto Marini¹², Carlos Rabello Jr¹³, Cristina Magalhaes¹⁴, Melissa Fraga¹⁵, Marcia Bandeira¹⁶, Iloite Scheibel¹⁷, Isabela Daud², Beatriz Carneiro², Claudio Len¹⁸, Clovis Silva¹⁹ and Claudia Magalhaes²⁰, ¹Universidade Estadual Paulista (UNESP) Botucatu, Brazil, ²Instituto da Criança - Universidade de São Paulo (USP), São Paulo, Brazil, ³Universidade Federal da Bahia, Brazil, ⁴Universidade Federal do Para, Brazil, ⁵Universidade Federal do Rio de janeiro, Rio de Janeiro, ⁶Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Brazil, ⁷Universidade de Sao Paulo- Ribeirao Preto, São Paulo, Brazil, ⁸Hospital Albert Sabin, Brazil, ⁹Santa Casa de Sao Paulo, Brazil, ¹⁰UNIFESP, São Paulo, Brazil, ¹¹University of Campinas, Campinas, Sao Paulo, Brazil, ¹²UNICAMP, São Paulo, Brazil, ¹³Hospital Geral de Fortaleza, Brazil, ¹⁴Hospital Jose de Alencar - Brasilia, Brazil, ¹⁵Hospital Darcy Vargas, Brazil, ¹⁶Hospital Pequeno Principe- Curitiba, Brazil, ¹⁷Hospital Conceição de Porto Alegre, Brazil, ¹⁸Universidade Federal de São Paulo - Unifesp, São Paulo, Brazil, ¹⁹Universidade de São Paulo, São Paulo, Brazil, ²⁰São Paulo State University, Pediatric Rheumatology Division, Botucatu, Brazil
Background/Purpose: Muscle weakness is often progressive and persistent in Juvenile Dermatomyositis (JDM). Muscle strength testing is useful for evaluating severity of muscle weakness. There is…
Abstract Number: L10 • ACR Convergence 2022
Efgartigimod Prevents Necrosis and Allows for Muscle Fiber Regeneration in a Humanized Mouse Model of Immune-mediated Necrotizing Myopathy (IMNM)
Sarah Julien¹, Emma Briand¹, Bas van der Woning², Leentje de ceuninck³, Rachid zoubari¹, olivier benveniste⁴, laurent drouot¹ and olivier boyer⁵, ¹INSERM U1234, PAn’THER FOCIS Center of Excellence, Rouen, France, ²argenx, Boston, MA, ³argenx, Ghent, Belgium, ⁴AP-HP, Pitié-Salpêtrière University Hospital, Department of Internal Medicine and Clinical Immunology, Paris, France, ⁵INSERM U1234, PAn’THER FOCIS Center of Excellence; Rouen University Hospital, Department of Immunology and Biotherapy, Rouen, France
Background/Purpose: Immune-mediated necrotizing myopathy (IMNM) is a severe form of myositis characterized by muscle weakness and elevated creatine kinase levels in serum. The most frequent…
Abstract Number: 0003 • ACR Convergence 2022
Rituximab versus Cyclophosphamide for the Treatment of Connective Tissue Disease Associated Interstitial Lung Disease (RECITAL): A Sub-group Analysis of a Multi-centre Randomised Controlled Trial
Toby Maher¹, Veronica Tudor², Peter Saunders³, Michael Gibbons⁴, Sophie Fletcher⁵, Helen Parfrey⁶, Chris Denton⁷, Rachel Hoyles³, Elizabeth Renzoni², Maria Kokosi², Athol Wells², Deborah Ashby⁸, Matyas Szigeti⁸ and Philip Molyneaux⁸, ¹University of Southern California, Los Angeles, CA, ²Royal Brompton Hospital, London, United Kingdom, ³Oxford University Hospitals, Oxford, United Kingdom, ⁴Royal Devon and Exeter Hospital, Exeter, United Kingdom, ⁵Southampton University Hospitals, Southampton, United Kingdom, ⁶Addenbrookes Hospital, Cambridge, United Kingdom, ⁷University College London, London, United Kingdom, ⁸Imperial College London, London, United Kingdom
Background/Purpose: The RECITAL trial (NCT01862926) compared rituximab to cyclophosphamide as first line therapy for patients with severe or progressive interstitial lung disease due to idiopathic…
Abstract Number: 0166 • ACR Convergence 2022
Detection of the Novel Autoantibodies Against Transcription Factor Sp4 Is Related with Low Risk of Cancer in Idiopathic Inflammatory Myopathy Patients
Yuji Hosono¹, Azusa Kojima¹, Akira Ishii¹, Mai Sugiyama¹, Yuto Izumi¹, Noriko Sasaki², Chiho Yamada¹ and Shinji Sato¹, ¹Tokai University School of Medicine, Isehara Kanagawa, Japan, ²Tokai University School of Medicine, sagamihara-city, Japan
Background/Purpose: In idiopathic inflammatory myopathy (IIM), many kinds of autoantibodies are often detected and associated with each clinical phenotype. Recently, autoantibody against transcription factor Sp4…
Abstract Number: 1453 • ACR Convergence 2022
Prevalence and Associations of Myositis in an Indian Inception Cohort of Lupus
Liza Rajasekhar¹, Vineetha Shobha², Meenakshi Ponnana³, Chengappa Kavadichanda⁴, Ashish J Mathew⁵, Saumya Ranjan Tripathy⁶, Manish Rathi⁷, Parasar Ghosh⁸, Ranjan Gupta⁹, Avinash Jain¹⁰ and Amita Aggarwal¹¹, ¹Nizam's Institute of Medical Sciences, Madhapur, India, ²St. John’s Medical College Hospital, Bangalore, India, ³Nizam's Institute of Medical Sciences, Hyderabad, India, ⁴JIPMER, Pondicherry, Puducherry, India, ⁵Rigshospitalet, Copenhagen, Denmark, ⁶SCB medical college, Cuttack, India, ⁷PGIMER Chandigarh, Chandigarh, India, ⁸Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁹All India Institute of Medical Sciences, New Delhi, India, ¹⁰SMS Medical College, Lucknow, India, ¹¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Muscle inflammation in systemic lupus erythematosus (SLE) usually presents as generalised myalgia in the presence of active disease elsewhere and responds well to treatment.…
Abstract Number: 1878 • ACR Convergence 2022
Identification of Serum Biomarkers Associated with Muscle Inflammation Detected on MRI in Polymyositis/dermatomyositis
Haruna Matsuo¹, Toshimasa Shimizu¹, Tomohiro Koga¹, Nozomi Oki², Masataka Uetani² and Atsushi Kawakami³, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Radiological Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
Background/Purpose: Muscle inflammation is a major clinical manifestation in patients with polymyositis/dermatomyositis (PM/DM). Phenotypes of PM/DM patients, especially those with interstitial lung diseases, are known…
Abstract Number: 0035 • ACR Convergence 2022
Anti-Peroxiredoxin 6 and Anti- Myosin Light Polypeptide 6 Autoantibodies with Interstitial Lung Disease and Severe Disease in Juvenile Dermatomyositis
Rie Karasawa¹, James Jarvis², Toshiko Sato¹, Megumi Tanaka¹, Terrance P O'Hanlon³, Payam Noroozi-Farhadi⁴, Willy A. Flegel⁵, Kazuo Yudoh¹ and Lisa G Rider³, ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Department of Pediatrics, University at Buffalo Clinical and Translational Research Center, Buffalo, NY, ³Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD, ⁴NIEHS, NIH, Garrett Park, MD, ⁵NIH, Garrett Park, MD
Background/Purpose: Juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis (JDM) are among the most common forms of inflammatory rheumatic diseases in children. Anti-endothelial cell antibodies (AECA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].